New Technology Propels Cell-Based Diagnostics

New technology combinations and innovations are expected to propel the cell-based diagnostic market to nearly US$9 billion by 2011.

Cell-based diagnostics with applications in hematology, histology, cytology, microbiology, and transplant medicine are being influenced by emerging technologies that will propel certain segments of the market forward at double-digit rates, according to a new report released by market research company Kalorama Information (New York, NY, USA).

The report evaluates the market for both traditional technologies such as flow cytometry and traditional stains, as well as sophisticated molecular techniques, microarrays, and beadarrays. These new technologies and digital arrays are well suited to feed data to software designed to interpret array patterns and create the test result.

In addition, new methods for genotyping biopsied tissue could revolutionize the treatment of a number of diseases, including diabetes, cancer, autoimmune, and neurodegenerative diseases. This could lead the way to an era of individualized patient therapies using microarrays, biochips, polymerase chain reaction (PCR), and in situ hybridization, according to Kalorama Information.

"The potential for these technologies is huge,” noted Shara Rosen, analyst for Kalorama Information and author of the report. "In fact, while our current market evaluations are based on commercialized assays and reagents, there is also a vast menu of in-lab developed, or ‘home-brew' tests using tissue stains, flow reagents, antibodies, molecular probes, and dyes marketed by scores of companies, worldwide. As the science of cell diagnostics is perfected, many of these tests are going main stream as authorized test services or market-cleared tests.”


Related Links:
Kalorama Information